Pulmonary Embolism Market Size, Share, and Industry Analysis, By Drug Class (Factor Xa Inhibitors, Thrombin Inhibitors, Heparin, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Pulmonary embolism is a serious and potentially life-threatening condition where a blood clot blocks an artery in the lungs. This condition typically occurs due to the formation of clots in a deep vein, often in the leg, and is transported to the lungs. The symptoms of this disease comprise sudden shortness of breath, chest pain, and rapid heart rate. Pulmonary embolism requires prompt medical treatment, usually with anticoagulant medications, to dissolve the clot and for the prevention of further complications. The risk factors for this disease include recent surgery, prolonged immobility, cancers, pregnancy, and certain genetic conditions. Pulmonary embolism can lead to permanent lung damage, heart failure, and even death if left untreated.

The market growth is primarily attributed to the rising incidence of pulmonary embolism globally. This is expected to increase the demand for treating such conditions, which is expected to boost the adoption of anticoagulant drugs, thereby driving the market growth in the coming years.

• For instance, according to the article published by the American Lung Association in January 2024, an estimated 900,000 people in the U.S. are affected by pulmonary embolism in the U.S.

Furthermore, this rising incidence of the disease is primarily attributed to the increase in the number of cancer patients, people receiving hormone replacement therapy, and deep vein thrombosis (DVT). These factors elevate the risk of blood clotting, inducing the pulmonary embolism. This is expected to surge the demand for the treatment of pulmonary embolism, thereby propelling the market growth.

• For instance, according to an article published by the American Lung Association in January 2024, deep vein thrombosis leads to pulmonary embolism development in most cases.

The high burden of pulmonary embolism is further increasing the awareness and propelling the diagnosis rates of such conditions, which, in turn, is expected to surge the demand for treatment with anticoagulant drugs, fueling the market growth in the coming years.

The COVID-19 pandemic significantly impacted the global pulmonary embolism market in 2020. The pandemic caused a significant increase in the incidence of pulmonary embolism (PE) among hospitalized COVID-19 patients, with studies reporting PE rates of 21.8% in COVID-19 patients, especially those in intensive care. This surged the market growth during the pandemic.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Key Diseases, by Key Countries/Region, 2023
• Pipeline Analysis
• New Product Launches By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market   

Analysis by Drug Class

Based on the drug class, the market is divided into Factor Xa inhibitors, thrombin inhibitors, heparin, and others. The factor Xa inhibitors segment is projected to account for a significant share of the global pulmonary embolism market during the forecast period. The growth of this segment is attributed to a preferred use of these drugs as anticoagulants for the treatment of blood clots in pulmonary embolism. Furthermore, these drugs treat various other conditions related to this disease, including deep vein thrombosis, coronary artery disease, and peripheral artery disease, which makes them the drug of choice for pulmonary embolism. In consideration of these benefits, several prominent players are ensuring the availability of such drugs to meet the global demand, which is expected to boost the segment growth in the coming years.

• For instance, as of June 2024, Bristol-Myers Squibb Company manufactures ELIQUIS, which is supplied by Pfizer Inc. globally for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT).

On the other hand, the thrombin inhibitors segment is anticipated to grow at a substantial CAGR during the forecast period. The segment's growth is attributed to its comparable benefits with factor Xa inhibitors for treating pulmonary embolism. This is expected to boost its adoption in the coming years, propelling the market growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the pulmonary embolism market during the forecast period. The market growth of the region is attributed to the presence of prominent players contributing to the high penetration rate of anticoagulant drugs such as factor Xa inhibitors and thrombin inhibitors. Moreover, the higher recommendation of physicians for such medication is increasing the adoption of anticoagulant drugs in the region, which is expected to boost the market growth during the projection period.

• For instance, as of June 2024, the XARELTO manufactured by Janssen Pharmaceuticals, Inc. has been prescribed over 80 million times in the U.S. alone.

Asia Pacific is projected to grow significantly during the forecast timeframe. The region's growth is mainly attributed to the increasing patient pool, which represents a significant opportunity for key players to improve their regional distribution network. This is expected to increase the penetration rate of such drugs in the key countries of the region, fueling the market growth in the forthcoming years.

Key Players Covered

The market consists of significant players, such as Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., DAIICHI SANKYO COMPANY, LIMITED., Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., and Pfizer Inc.

Key Industry Developments

• In June 2024, Alembic Pharmaceuticals Limited received the abbreviated new drug application (ANDA) approval of dabigatran etexilate capsules in strengths of 75 and 150 mg and a tentative approval for the 110 mg variant. These capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adults.
• In January 2021, Verseon International Corporation received yet another patent from the European Patent Office related to its novel class of direct thrombin inhibitors for deep-vein thrombosis, pulmonary embolisms, atrial fibrillation, acute coronary syndrome, and others.